Answers are grounded in this paper and cite their sources.
Laboratory staff and clinicians should be aware of the risk for biotin interference, paying particular attention to results from certain patient groups (e.g., patients with multiple sclerosis) or results that do not fit the overall clinical picture."
No takes yet. Share an insight, caveat, or question.
Luca Giovanella (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: